BG Medicine Q2 Revenues Spike; Company Withdraws FDA Submission for CardioScore Test | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine said today that revenues for the second quarter increased 181 percent year over year, surpassing the consensus Wall Street estimates on the top and bottom line.

For the three months ended June 30, the Waltham, Mass.-based company recorded $622,000 in revenues, up from $221,000 a year ago, beating the average analyst estimate of $520,000. Product revenues spiked to $566,000 from $46,000 a year ago, "reflecting increasing demand for the BGM Galectin-3 test," BG Medicine said, while service revenues dropped to $56,000 from $175,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.